In vitro topo II--DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2001-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0145-2126(00)00103-XPMID 11166828
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Etoposide‐induced DNA strand breaks in relation to p‐glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL

  1999cited by this paper
• Topoisomerase II-mediated alterations of K562 drug resistant sublines

  1999cited by this paper
• The role of DNA mismatch repair in drug resistance.

  1998cited by this paper
• Chronic lymphocytic leukaemia in the Bloemfontein academic hospitals.

  1998cited by this paper
• Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.

  1997cited by this paper
• Interleukin-9 in human myeloid leukemia cells.

  1997cited by this paper
• Drug resistance mechanisms in chronic lymphocytic leukemia.

  1996cited by this paper
• DNA damage induced by etoposide; a comparison of two different methods for determination of strand breaks in DNA.

  1996cited by this paper
• Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia.

  1996cited by this paper
• Apoptosis and Cancer Chemotherapy

  1996cited by this paper
• MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.

  1996cited by this paper
• Interleukin-9 stimulates the proliferation of human myeloid leukemic cells.

  1996cited by this paper
• DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.

  1995cited by this paper
• Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.

  1994cited by this paper
• Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.

  1994cited by this paper
• Apoptosis in cancer therapy: crossing the threshold.

  1994cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper
• Induction of DNA strand breaks associated with apoptosis during treatment of leukemias.

  1993cited by this paper
• bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair.

  1993cited by this paper
• In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.

  1993cited by this paper
• Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia.

  1992cited by this paper
• Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.

  1992cited by this paper
• Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.

  1991cited by this paper
• Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators

  1991cited by this paper
• Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.

  1990cited by this paper
• In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions

  1990cited by this paper
• In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

  1990cited by this paper
• Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.

  1989cited by this paper
• Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

  1989cited by this paper
• DNA topoisomerase poisons as antitumor drugs.

  1989influential reference
• Altered function of DNA topoisomerases as a basis for antineoplastic drug action.

  1988cited by this paper
• Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.

  1988cited by this paper
• Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins.

  1988cited by this paper
• Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).

  1987cited by this paper
• The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).

  1986cited by this paper
• Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.

  1986cited by this paper
• Cleavage of DNA by mammalian DNA topoisomerase II.

  1983cited by this paper
• Nucleosomes contain DNA binding proteins that resist dissociation by sodium dodecyl sulfate.

  1983cited by this paper
• Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells.

  1981cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Mitochondrial metabolism as a target for acute myeloid leukemia treatment

  2021cites this paper
• Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.

  2016cites this paper
• Further constituents of Galianthe thalictroides (Rubiaceae) and inhibition of DNA topoisomerases I and IIα by its cytotoxic β-carboline alkaloids.

  2014cites this paper
• Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.

  2010cites this paper
• Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage

  2010cites this paper
• Repair of idarubicin-induced DNA damage: a cause of resistance?

  2007cites this paper
• Modification of biomolecules by lipoxidation-derived aldehydes.

  2006cites this paper
• Topoisomerase II inhibitors.

  2006cites this paper
• In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia

  2005cites this paper
• Interference by Anti-Cancer Chemotherapeutic Agents in the MTT-Tumor Chemosensitivity Assay

  2004cites this paper
• Topoisomerase II inhibitors.

  2003cites this paper
• 2-[4-(7-Chloro-2-quinoxalinyloxyphenoxy]-propionic Acid (XK469), an Inhibitor of Topoisomerase (Topo) II (cid:1) , Up-Regulates Topo II (cid:2) and Enhances Topo II (cid:2) -mediated Cytotoxicity 1

  2002cites this paper
• Application of in vitro chemosensitivity testing for evaluation of new cytotoxic drugs in chronic lymphocytic leukaemia.

  2002cites this paper
• 2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.

  2002cites this paper